GLSI · Greenwich LifeSciences Inc
United States · RS rating 53 · As of 2026-11-03
| Price | 15.92 USD |
|---|---|
| 1-day change | -3.3% |
| RS rating (overall / 1M / 3M / 12M) | 53 / 43 / 82 / 91 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 27 / 28 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +52.6% |
| Market cap (USD) | $327.9M |